EC Number   |
Protein Variants |
Reference |
|---|
   3.6.5.1 | A26G |
mutant, rate of poly(U)-directed poly(Phe) synthesis and the ribosome-dependent GTPase activity are decreased, the catalytic efficiency of the intrinsic SsEF-2 GTPase triggered by ethylene glycol is enhanced |
679626 |
| 3.6.5.1 | C351G |
mutation of Gi1alpha or Gi3alpha, pertussis toxin-resistant mutant |
644100 |
| 3.6.5.1 | C352G |
mutation of Gi2alpha, pertussis toxin-resistant mutant |
644100 |
| 3.6.5.1 | CFP-TM-Galpha |
consists of a cleavable signal peptide from human growth hormone, enhanced CFP, the amino-terminal amino acids of the rat mu-opioid receptor, including TM1 and intracellular loop1, and the human Galpha subunit |
676909 |
| 3.6.5.1 | CFP-TM-Galphai3 |
C to G mutation at the -4 position to render them insensitive to PTX-mediated ADP-ribosylation |
676909 |
| 3.6.5.1 | CFP-TM-GalphaoA |
C to G mutation at the -4 position to render them insensitive to PTX-mediated ADP-ribosylation |
676909 |
| 3.6.5.1 | CFP-TM-GalphaQ205L |
active mutant |
676909 |
| 3.6.5.1 | CFP-TM-Galphasq5 |
the five aminoacids normally found in the carboxyl terminus of Galphas, QYELL, are replaced with those normally found in the carboxy terminus of Galphaq, EYNLV |
676909 |
| 3.6.5.1 | E92A/N93A |
RGS14 mutant |
671822 |
| 3.6.5.1 | E92A/N93A/R519F |
RGS14 mutant |
671822 |
